Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.12
-1.01 (-7.15%)
At close: Nov 20, 2024, 4:00 PM
13.04
-0.08 (-0.61%)
Pre-market: Nov 21, 2024, 7:19 AM EST
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $9.11M in the quarter ending September 30, 2024, a decrease of -24.02%. This brings the company's revenue in the last twelve months to $43.09M, down -16.77% year-over-year. In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, down -30.40%.
Revenue (ttm)
$43.09M
Revenue Growth
-16.77%
P/S Ratio
29.23
Revenue / Employee
$81,913
Employees
526
Market Cap
1.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
InMode | 423.75M |
BioCryst Pharmaceuticals | 412.58M |
Kiniksa Pharmaceuticals International, | 384.10M |
Travere Therapeutics | 203.45M |
Schrödinger | 193.35M |
Harrow | 169.14M |
Arvinas | 161.10M |
Ocular Therapeutix | 61.44M |
NTLA News
- 2 days ago - Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha
- 4 days ago - Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewsWire
- 9 days ago - Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus - Seeking Alpha
- 13 days ago - Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 15 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - GlobeNewsWire
- 26 days ago - Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity - Seeking Alpha